DGX Quest Diagnostics Incorporated Common Stock
$240,56
Kurs · Aug 21, 2026
Fundamentaldaten per Jul 23, 2026
52W-Spanne
$171–$246
93% of range
Analystenbewertung
HOLD
23 analysts
Kursziel
$246
+2% upside
P/E (TTM)
27.7
ROE
14.2%
Nettogewinnmarge
9.0%
Über Quest Diagnostics Incorporated Common Stock Unternehmensübersicht von Wikipedia
Quest Diagnostics Inc. ist ein US-amerikanisches Unternehmen im Bereich der klinischen Labordiagnostik und Gesundheitsinformation. Der Hauptsitz befindet sich in Secaucus. Nach Angaben der Nachrichtenagentur Reuters war Quest Diagnostics 2013 das größte Labortest-Unternehmen in den USA. 2024 betrug der Jahresumsatz etwa 9,87 Mrd. US-Dollar bei rund 55.000 Beschäftigten. Die Aktie des Unternehmens wird an der New Yorker Börse gehandelt und Quest Diagnostics ist ein Bestandteil des Leitindex S&P-500.
Mehr lesen
Quest Diagnostics Inc. ist ein US-amerikanisches Unternehmen im Bereich der klinischen Labordiagnostik und Gesundheitsinformation. Der Hauptsitz befindet sich in Secaucus (New Jersey). Nach Angaben der Nachrichtenagentur Reuters war Quest Diagnostics 2013 das größte Labortest-Unternehmen in den USA. 2024 betrug der Jahresumsatz etwa 9,87 Mrd. US-Dollar bei rund 55.000 Beschäftigten. Die Aktie des Unternehmens wird an der New Yorker Börse gehandelt und Quest Diagnostics ist ein Bestandteil des Leitindex S&P-500.
Geschichte
Das Unternehmen wurde 1967 von Dr. Paul A. Brown in New York City gegründet. Ursprünglich firmierte es unter dem Namen Metropolitan Pathology Laboratories (MetPath). 1982 übernahm der Glas- und Chemiekonzern Corning MetPath, das daraufhin als Corning Clinical Laboratories weitergeführt wurde. Ende 1996 spaltete Corning seine Labordienste (Corning Clinical Laboratories) in ein eigenständiges Unternehmen aus und nannte es Quest Diagnostics Incorporated. Quest Diagnostics wurde am 31. Dezember 1996 an die Corning-Aktionäre ausgegeben und daraufhin an der NYSE gelistet. Zu diesem Zeitpunkt beschäftigte Quest bereits rund 18.700 Mitarbeiter und erwirtschaftete 1995 einen Umsatz von etwa 1,6 Mrd. USD.
In den folgenden Jahren expandierte Quest Diagnostics vor allem durch Zukäufe. 2005 erwarb das Unternehmen LabOne (einen Anbieter von Drogentest- und Gesundheitsdiensten) für 930 Millionen USD. 2007 folgte die Übernahme von AmeriPath (einem nationalen Anbieter anatomisch-pathologischer und onkologischer Labordienstleistungen) für eine nicht genannte Kaufsumme. Weitere Übernahmen und Partnerschaften stärkten die Position von Quest als umfassender Labordienstleister. Im September 2018 verlegte Quest Diagnostics den Firmensitz von Madison (New Jersey) nach Secaucus (New Jersey), wo sich heute die Konzernzentrale befindet.
Tätigkeit
Quest Diagnostics betreibt ein landesweites Netzwerk diagnostischer Labore, Patientenentnahmestellen und Logistikdienste. Nach Unternehmensangaben umfasst dieses Netzwerk etwa 2.400 eigene Patientenservicezentren sowie insgesamt rund 8.000 Anlaufstellen für Proben (inklusive mobiler Blutentnahme-Services). In Dutzenden Laboren quer durch die USA werden pro Jahr Abermillionen von Untersuchungen durchgeführt. Insgesamt bietet Quest Diagnostics mehrere tausend unterschiedliche Laboruntersuchungen an – von einfachen Blutwerten über molekulargenetische und mikrobiologische Tests bis zu spezialisierten Analysen etwa in den Bereichen Frauenheilkunde, Onkologie oder Infektionskrankheiten.
Daneben erbringt Quest Diagnostics auch spezifische Serviceleistungen im Gesundheitswesen. So bietet das Unternehmen unter anderem Programme für betriebliche Gesundheitsvorsorge und Drogentests an, die von Arbeitgebern, Versicherungen und Behörden genutzt werden. Eigene Angaben zufolge werden jährlich etwa ein Drittel aller erwachsenen US-Bürger und rund die Hälfte aller US-Ärzte und Krankenhäuser durch Quest-Diagnostikdienste versorgt. In der COVID-19-Pandemie stellte Quest Diagnostics zusätzlich umfangreiche Testkapazitäten bereit – Berichten zufolge kam es dabei zeitweise zu Verzögerungen aufgrund der starken Nachfrage.
Kontroversen
Quest Diagnostics stellte im April 2009 einen Rekord auf, als es 302 Millionen Dollar an die Regierung zahlte, um einen Fall von Medicare-Betrug beizulegen, in dem dem Unternehmen vorgeworfen wurde, fehlerhafte medizinische Testkits verkauft zu haben. Es war die höchste Qui-Tam-Zahlung (Whistleblower), die jemals von einem medizinischen Labor für die Herstellung und den Vertrieb eines fehlerhaften Produkts geleistet wurde.
Im Mai 2011 zahlte Quest 241 Millionen Dollar an den Bundesstaat Kalifornien, um einen Fall nach dem False Claims Act beizulegen, in dem dem Unternehmen vorgeworfen wurde, Medi-Cal, das Medicaid-Programm des Bundesstaates, überhöhte Rechnungen gestellt und illegale Rückvergütungen als Anreiz für Gesundheitsdienstleister gezahlt zu haben, die Labore von Quest zu nutzen.
Quelle: Wikipedia, CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
DGX Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$240.56
Marktkapitalisierung
$26.70B
P/E (TTM)
27.7
EPS (TTM)
$8.75
Umsatz (TTM)
$11.04B
Dividendenrendite
1.3%
ROE
14.2%
Verschuldungsgrad
0.8
52W-Spanne
$171 – $246
DGX Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Configure
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz & Nettoergebnis
$11.04B
2016-12-31
→
2025-12-31
EPS
$8.75
2016-12-31
→
2025-12-31
Freier Cashflow
$1.36B
2016-12-31
→
2025-12-31
Margen
9.0%
2016-12-31
→
2020-12-31
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Kennzahl
5-Jahres-Trend
DGX
Peer-Median
P/E (TTM)
27.7
26.5
P/S (TTM) (K/V (TTM))
2.4
2.0
P/B (K/B)
3.7
4.9
EV / EBITDA
15.0
—
Price / FCF (Kurs / FCF)
19.6
—
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Kennzahl
5-Jahres-Trend
DGX
Peer-Median
Operating Margin (Betriebsgewinnmarge)
14.1%
—
Net Profit Margin (Nettogewinnmarge)
9.0%
4.0%
ROA
6.1%
5.0%
ROE
14.2%
15.2%
ROIC
9.2%
—
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Kennzahl
5-Jahres-Trend
DGX
Peer-Median
Debt / Equity (Fremdkapital / Eigenkapital)
0.8
—
Current Ratio (Liquiditätsgrad)
1.0
1.6
Quick Ratio
0.8
—
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kennzahl
5-Jahres-Trend
DGX
Peer-Median
Revenue YoY (Umsatz YoY)
11.8%
—
Revenue CAGR 3Y (Umsatz CAGR 3J)
3.7%
—
Revenue CAGR 5Y (Umsatz CAGR 5J)
3.2%
—
EPS YoY (EPS VjV)
13.8%
—
Net Income YoY (Nettogewinn YoY)
13.9%
—
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Kennzahl
5-Jahres-Trend
DGX
Peer-Median
Payout Ratio (Ausschüttungsquote)
35.6%
—
Dividenden Rendite, Ausschüttungsquote, Dividendenhistorie, 5-Jahres-CAGR
Dividendenrendite
1.3%
Ausschüttungsquote
35.6%
5J Div CAGR
—
| Ex-Datum | Betrag |
|---|---|
| 8. Juli 2026 | $0,8600 |
| 6. April 2026 | $0,8600 |
| 13. Januar 2026 | $0,8000 |
| 3. Oktober 2025 | $0,8000 |
| 7. Juli 2025 | $0,8000 |
| 7. April 2025 | $0,8000 |
| 14. Januar 2025 | $0,7500 |
| 4. Oktober 2024 | $0,7500 |
| 8. Juli 2024 | $0,7500 |
| 5. April 2024 | $0,7500 |
| 16. Januar 2024 | $0,7100 |
| 5. Oktober 2023 | $0,7100 |
| 10. Juli 2023 | $0,7100 |
| 6. April 2023 | $0,7100 |
| 17. Januar 2023 | $0,6600 |
| 3. Oktober 2022 | $0,6600 |
| 5. Juli 2022 | $0,6600 |
| 5. April 2022 | $0,6600 |
| 18. Januar 2022 | $0,6200 |
| 4. Oktober 2021 | $0,6200 |
DGX Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
KAUF
23 Analysten
- Starker Kauf 6 26,1%
- Kauf 7 30,4%
- Halten 10 43,5%
- Verkauf 0 0,0%
- Starker Verkauf 0 0,0%
12-Monats-Kursziel
15 Analysten · 2026-08-16
Median
$250.00
Jetzt
$240.56
Tief
$204.00
Hoch
$265.00
Median-Ziel
$250.00
+3,9%
Mittelwert-Ziel
$245.87
+2,2%
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
0.09%
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 30. Juni 2026 | $3.12 | $2.85 | 0.27% |
| 31. März 2026 | $2.50 | $2.37 | 0.13% |
| 31. Dezember 2025 | $2.42 | $2.38 | 0.04% |
| 30. September 2025 | $2.60 | $2.53 | 0.07% |
| 30. Juni 2025 | $2.62 | $2.60 | 0.02% |
| 31. März 2025 | $2.21 | $2.17 | 0.04% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| DGX | $19.09B | 19.8 | 11.8% | 9.0% | 14.2% | — |
| CVS | $100.87B | 57.1 | 7.8% | 0.44% | 2.4% | — |
| CI | $72.51B | 12.4 | 11.2% | 2.2% | 14.4% | — |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| GH | $13.34B | -30.8 | 32.9% | -42.4% | 205.7% | — |
| LH | $20.62B | 24.0 | 7.2% | 6.3% | 10.3% | 28.8% |
| BTSG | $7.20B | 43.0 | 28.2% | 1.5% | 10.8% | 11.8% |
| DVA | $7.79B | 11.5 | 6.5% | 5.5% | -281.8% | — |
| HIMS | — | 63.7 | 59.0% | 5.5% | 23.3% | 73.8% |
| HNGE | $0 | -6.0 | 50.6% | -89.9% | -299.8% | 79.7% |
| CHE | — | 23.3 | 4.1% | 10.5% | 24.4% | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 17
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | |
| Cost of Revenue | $7.37B | $6.63B | $6.20B | $6.45B | $6.58B | $5.80B | $5.04B | $4.93B | $4.72B | $4.62B | $4.66B | $4.64B | |
| Gross Profit | · | · | · | · | · | $3.63B | $2.69B | $2.60B | $2.68B | $2.90B | $2.84B | $2.80B | |
| SG&A Expense | $1.97B | $1.77B | $1.64B | $1.87B | $1.73B | $1.55B | $1.46B | $1.42B | $1.44B | $1.38B | $1.68B | $1.73B | |
| Operating Expenses | $9.48B | $8.53B | $7.99B | $8.46B | $8.41B | $7.47B | $6.50B | $6.43B | $6.24B | $5.94B | $6.09B | $6.45B | |
| Operating Income | $1.56B | $1.35B | $1.26B | $1.43B | $2.38B | $1.97B | $1.23B | $1.10B | $1.17B | $1.28B | $1.40B | $983M | |
| Interest Expense | · | · | $163M | $148M | $152M | $166M | $180M | $169M | $153M | $144M | $154M | $167M | |
| Interest Income | $13M | $25M | $11M | $10M | $1M | $3M | $5M | $2M | $2M | $1M | $1M | $3M | |
| Other Non-op | $26M | $30M | $20M | $-55M | $369M | $76M | $20M | $-8M | $16M | $-48M | $-143M | $4M | |
| Pretax Income | $1.32B | $1.18B | $1.13B | $1.24B | $2.60B | $1.88B | $1.08B | $926M | $1.03B | $1.09B | $1.10B | $823M | |
| Income Tax | $314M | $273M | $248M | $264M | $597M | $460M | $247M | $182M | $241M | $429M | $373M | $262M | |
| Net Income | $992M | $871M | $854M | $946M | $2.00B | $1.43B | $858M | $736M | $772M | $645M | $709M | $556M | |
| EPS (Basic) | $8.87 | $7.78 | $7.59 | $8.10 | $15.85 | $10.62 | $6.36 | $5.39 | $5.63 | $4.58 | $4.92 | $3.83 | |
| EPS (Diluted) | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 | $10.47 | $6.28 | $5.29 | $5.50 | $4.51 | $4.87 | $3.81 | |
| Shares (Basic) | 111,000,000 | 111,000,000 | 112,000,000 | 116,000,000 | 125,000,000 | 134,000,000 | 134,000,000 | 136,000,000 | 137,000,000 | 140,000,000 | 144,000,000 | 145,000,000 | |
| Shares (Diluted) | 113,000,000 | 113,000,000 | 113,000,000 | 118,000,000 | 128,000,000 | 136,000,000 | 136,000,000 | 139,000,000 | 140,000,000 | 142,000,000 | 145,000,000 | 145,000,000 | |
| EBITDA | $2.13B | $1.84B | $1.70B | $1.86B | $2.79B | $2.33B | $1.56B | $1.41B | $1.44B | $1.53B | $1.70B | $1.30B |
Bilanz 27
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $420M | $549M | $686M | $315M | $872M | $1.16B | $1.19B | $135M | $137M | $359M | $133M | $192M | |
| Receivables | $1.41B | $1.30B | $1.21B | $1.20B | $1.44B | $1.52B | $1.06B | $1.01B | $924M | $926M | $901M | $932M | |
| Inventory | $189M | $188M | $190M | $192M | $208M | $223M | $123M | $99M | $95M | $82M | $84M | $110M | |
| Prepaid Expense | $361M | $351M | $286M | $196M | $223M | $157M | $112M | $144M | $150M | $155M | $207M | $186M | |
| Current Assets | $2.38B | $2.39B | $2.37B | $1.90B | $2.74B | $3.06B | $2.49B | $1.39B | $1.31B | $1.53B | $1.50B | $1.60B | |
| PP&E (Net) | $2.20B | $2.11B | $1.82B | $1.77B | $1.71B | $1.63B | $1.45B | $1.29B | $1.15B | $1.03B | $925M | $933M | |
| PP&E (Gross) | $6.18B | $5.77B | $5.23B | $5.10B | $4.79B | $4.62B | $4.23B | $3.97B | $3.67B | $3.43B | $3.23B | $3.13B | |
| Accum. Depreciation | $3.97B | $3.66B | $3.42B | $3.34B | $3.09B | $2.99B | $2.78B | $2.68B | $2.53B | $2.40B | $2.31B | $2.19B | |
| Goodwill | $8.95B | $8.86B | $7.73B | $7.22B | $7.09B | $6.87B | $6.62B | $6.56B | $6.33B | $6.00B | $5.91B | $6.03B | |
| Intangibles | $1.64B | $1.76B | $1.17B | $1.09B | $1.17B | $1.17B | $1.12B | $1.21B | $1.12B | $949M | $984M | $1.07B | |
| Other Non-current Assets | $270M | $255M | $198M | $144M | $163M | $176M | $160M | $119M | $136M | $148M | $174M | $172M | |
| Total Assets | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B | $9.96B | $9.86B | |
| Accounts Payable | $1.60B | $1.39B | $1.36B | $1.40B | $1.60B | $1.63B | $1.04B | $1.02B | $1.02B | $975M | $1.01B | $1.19B | |
| Accrued Liabilities | $338M | $306M | $287M | $392M | $460M | $356M | $223M | $274M | $246M | $254M | $257M | $277M | |
| Current Liabilities | $2.28B | $2.17B | $1.81B | $1.55B | $1.75B | $1.78B | $1.99B | $1.49B | $1.06B | $981M | $1.17B | $1.71B | |
| Capital Leases | $537M | $535M | $503M | $489M | $494M | $499M | $413M | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $264M | $243M | $170M | $191M | $157M | $204M | |
| Other Non-current Liabilities | $957M | $938M | $876M | $812M | $792M | $847M | $711M | $745M | $663M | $654M | $514M | $594M | |
| Long-term Debt | $5.67B | $6.22B | $4.71B | $3.98B | $4.01B | $4.01B | $4.77B | $3.89B | $3.78B | $3.73B | $3.65B | $3.74B | |
| Total Debt | $5.67B | $6.22B | $4.71B | $3.98B | $4.01B | $4.01B | $4.77B | $3.89B | $3.78B | $3.73B | $3.65B | $3.76B | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Retained Earnings | $9.99B | $9.36B | $8.82B | $8.29B | $7.65B | $9.30B | $8.17B | $7.60B | $7.14B | $6.61B | $6.20B | $5.72B | |
| Treasury Stock | $5.18B | $4.86B | $4.83B | $4.67B | $3.45B | $5.37B | $5.22B | $5.00B | $4.78B | $4.46B | $3.96B | $3.81B | |
| AOCI | $-27M | $-88M | $-14M | $-21M | $-14M | $-21M | $-39M | $-59M | $-48M | $-72M | $-38M | $-27M | |
| Stockholders' Equity | $7.17B | $6.78B | $6.31B | $5.89B | $6.44B | $6.76B | $5.64B | $5.22B | $4.92B | $4.63B | $4.68B | $4.30B | |
| Liabilities + Equity | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B | $14.03B | $12.84B | $11.00B | $10.50B | $10.10B | $9.96B | $9.86B | |
| Shares Outstanding | 110,000,000 | 111,000,000 | 111,000,000 | 111,000,000 | 119,000,000 | 133,000,000 | 133,000,000 | 135,000,000 | 135,000,000 | 137,000,000 | 143,000,000 | 144,000,000 |
Cashflow 17
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $570M | $493M | $439M | $437M | $408M | $361M | $329M | $309M | $270M | $249M | $304M | $314M | |
| Stock-based Comp | $88M | $88M | $77M | $77M | $79M | $97M | $56M | $61M | $79M | $69M | $52M | $51M | |
| Deferred Tax | $105M | $13M | $-49M | $1M | $-57M | $85M | $15M | $73M | $9M | $37M | $112M | $23M | |
| Amort. of Intangibles | $154M | $127M | $108M | $120M | $103M | $103M | $96M | $90M | $74M | $72M | $81M | $94M | |
| Restructuring | · | · | · | $55M | $13M | $14M | $-3M | $49M | $30M | $11M | $39M | $43M | |
| Other Non-cash | $131M | $-131M | $-49M | $257M | $-192M | $31M | $-15M | $21M | $45M | $69M | $-367M | $-6M | |
| Operating Cash Flow | $1.89B | $1.33B | $1.27B | $1.72B | $2.23B | $2.00B | $1.24B | $1.20B | $1.18B | $1.12B | $821M | $944M | |
| CapEx | $527M | $425M | $408M | $404M | $403M | $418M | $400M | $383M | $252M | $293M | $263M | $308M | |
| Investing Cash Flow | $-631M | $-2.55B | $-1.06B | $-543M | $21M | $-772M | $-411M | $-801M | $-830M | $-127M | $-362M | $-1.02B | |
| Stock Repurchased | $450M | $151M | $275M | $1.41B | $2.20B | $325M | $353M | $322M | $465M | $590M | $224M | $132M | |
| Net Stock Activity | $-450M | $-151M | $-275M | $-1.41B | $-2.20B | $-325M | $-353M | $-322M | $-465M | $-590M | $-224M | $-132M | |
| Dividends Paid | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M | $212M | $187M | |
| Financing Cash Flow | $-1.39B | $1.08B | $160M | $-1.73B | $-2.54B | $-1.27B | $225M | $-401M | $-592M | $-738M | $-518M | $86M | |
| Net Change in Cash | $-129M | $-137M | $371M | $-557M | $-286M | · | · | · | $-222M | $226M | $-59M | $5M | |
| Taxes Paid | $169M | $256M | $317M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $1.36B | $909M | $864M | $1.31B | $1.83B | $1.59B | $843M | $817M | $923M | $776M | $547M | $630M | |
| Levered FCF | · | · | $737M | $1.20B | $1.71B | $1.46B | $704M | $681M | $806M | $689M | · | · |
Rentabilität 8
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 38.5% | 34.8% | 34.6% | 38.8% | 38.6% | 37.9% | 37.6% | |
| Operating Margin | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% | 20.9% | 15.9% | 14.6% | 15.1% | 17.0% | 18.7% | 13.2% | |
| Net Margin | 9.0% | 8.8% | 9.2% | 9.6% | 18.5% | 15.2% | 11.1% | 9.8% | 10.0% | 8.6% | 9.5% | 7.5% | |
| Pretax Margin | 11.9% | 11.9% | 12.2% | 12.5% | 24.1% | 20.0% | 13.9% | 12.3% | 13.4% | 14.4% | 14.7% | · | |
| EBITDA Margin | 19.3% | 18.6% | 18.4% | 18.9% | 25.9% | 24.7% | 20.2% | 18.7% | 18.6% | 20.3% | 22.7% | 17.4% | |
| ROA | 6.1% | 5.8% | 6.4% | 7.1% | 14.4% | 10.7% | 7.2% | 6.8% | 7.5% | 6.4% | 7.1% | 5.9% | |
| ROE | 14.2% | 13.3% | 14.0% | 15.3% | 30.2% | 23.1% | 15.8% | 14.5% | 16.2% | 13.9% | 15.8% | 13.5% | |
| ROIC | 9.2% | 8.0% | 8.9% | 11.4% | 17.5% | 13.8% | 9.1% | 9.7% | 10.2% | 9.2% | 11.1% | · |
Liquidität & Solvenz 5
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 1.1 | 1.3 | 1.2 | 1.6 | 1.7 | 1.3 | 0.9 | 1.2 | 1.6 | 1.3 | 0.9 | |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 1.0 | 1.3 | 1.5 | 1.1 | 0.8 | 1.0 | 1.3 | 0.9 | 0.7 | |
| Debt / Equity | 0.8 | 0.9 | 0.7 | 0.7 | 0.6 | 0.6 | 0.8 | 0.7 | 0.8 | 0.8 | 0.8 | 0.9 | |
| LT Debt / Equity | 0.7 | 0.8 | 0.7 | 0.7 | 0.6 | 0.6 | 0.7 | 0.7 | 0.8 | 0.8 | 0.7 | 0.8 | |
| Interest Coverage | · | · | 7.7 | 9.6 | 15.7 | 11.9 | 6.8 | 6.5 | 7.6 | 8.9 | · | · |
Effizienz 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.7 | 0.7 | 0.7 | 0.8 | 0.7 | 0.6 | 0.7 | 0.7 | 0.7 | 0.8 | 0.8 | |
| Inventory Turnover | 39.1 | 35.1 | 32.5 | 32.2 | 30.5 | 33.5 | 45.4 | 50.8 | 53.3 | 55.6 | 48.0 | 46.1 | |
| Receivables Turnover | 8.1 | 7.9 | 7.7 | 7.5 | 7.3 | 7.3 | 7.4 | 7.8 | 8.3 | 8.2 | 8.2 | 8.3 |
Wachstumsraten 10
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 11.8% | 6.7% | -6.4% | -8.4% | 14.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 3.7% | -2.9% | -0.66% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 3.2% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 13.8% | 2.7% | -6.0% | -48.8% | 48.5% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 3.2% | -20.9% | -10.6% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -3.5% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 13.9% | 2.0% | -9.7% | -52.6% | 39.4% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 1.6% | -24.1% | -15.8% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -7.1% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividend CAGR 5Y | 3.5% | · | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM) 16
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B | $9.44B | $7.73B | $7.53B | $7.40B | $7.21B | $7.49B | $7.43B | |
| Net Income TTM | $992M | $871M | $854M | $946M | $2.00B | $1.43B | $858M | $736M | $772M | $645M | $709M | $556M | |
| Market Cap | $19.09B | $16.75B | $15.30B | $17.36B | $20.59B | $15.85B | $14.20B | $11.24B | $13.30B | $12.59B | $10.17B | $9.66B | |
| Enterprise Value | $24.34B | $22.41B | $19.33B | $21.03B | $23.73B | $18.71B | $17.78B | $15.00B | $16.94B | $15.97B | $13.69B | $13.23B | |
| P/E | 19.8 | 19.6 | 18.4 | 19.6 | 11.1 | 11.4 | 17.0 | 15.7 | 17.9 | 20.4 | 14.6 | 17.6 | |
| P/S | 1.7 | 1.7 | 1.7 | 1.8 | 1.9 | 1.7 | 1.8 | 1.5 | 1.8 | 1.7 | 1.4 | 1.3 | |
| P/B | 2.7 | 2.5 | 2.4 | 2.9 | 3.2 | 2.3 | 2.5 | 2.2 | 2.7 | 2.7 | 2.2 | 2.2 | |
| P / Cash Flow | 10.1 | 12.6 | 12.0 | 10.1 | 9.2 | 7.9 | 11.4 | 9.4 | 11.3 | 11.8 | 12.6 | 10.3 | |
| P / FCF | 14.0 | 18.4 | 17.7 | 13.2 | 11.3 | 10.0 | 16.8 | 13.8 | 14.4 | 16.2 | 18.6 | 15.3 | |
| EV / EBITDA | 11.4 | 12.2 | 11.4 | 11.3 | 8.5 | 8.0 | 11.4 | 10.6 | 11.8 | 10.5 | 8.0 | 10.2 | |
| EV / FCF | 17.9 | 24.7 | 22.4 | 16.0 | 13.0 | 11.8 | 21.1 | 18.4 | 18.4 | 20.6 | 25.0 | 21.0 | |
| EV / Revenue | 2.2 | 2.3 | 2.1 | 2.1 | 2.2 | 2.0 | 2.3 | 2.0 | 2.3 | 2.2 | 1.8 | 1.8 | |
| Dividend Yield | 1.8% | 2.0% | 2.1% | 1.8% | 1.5% | 1.9% | 2.0% | 2.4% | 1.9% | 1.8% | 2.1% | 1.9% | |
| Earnings Yield | 5.0% | 5.1% | 5.4% | 5.1% | 9.0% | 8.8% | 5.9% | 6.3% | 5.6% | 4.9% | 6.9% | 5.7% | |
| Payout Ratio | 35.6% | 38.0% | 36.8% | 32.2% | 15.5% | 20.8% | 33.3% | 36.1% | 32.0% | 34.6% | 29.9% | 33.6% | |
| Annual Payout | $353M | $331M | $314M | $305M | $309M | $297M | $286M | $266M | $247M | $223M | $212M | $187M |
Gewinn- und Verlustrechnung 16
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.04B | $2.90B | $2.81B | $2.82B | $2.76B | $2.65B | $2.62B | $2.49B | $2.40B | $2.37B | $2.29B | $2.29B | $2.34B | $2.33B | $2.33B | $2.49B | |
| Cost of Revenue | $2.02B | $1.95B | $1.90B | $1.87B | $1.82B | $1.79B | $1.76B | $1.68B | $1.59B | $1.59B | $1.55B | $1.54B | $1.55B | $1.56B | $1.57B | $1.62B | |
| SG&A Expense | $529M | $504M | $504M | $501M | $486M | $476M | $466M | $448M | $416M | $440M | $407M | $380M | $416M | $439M | $563M | $464M | |
| Operating Expenses | $2.58B | $2.50B | $2.42B | $2.43B | $2.32B | $2.31B | $2.26B | $2.16B | $2.04B | $2.07B | $2.02B | $1.95B | $1.99B | $2.03B | $2.20B | $2.09B | |
| Operating Income | $459M | $399M | $386M | $386M | $438M | $346M | $361M | $330M | $355M | $300M | $267M | $342M | $348M | $305M | $135M | $392M | |
| Interest Expense | · | · | · | · | · | · | · | · | $47M | $49M | · | $41M | $39M | $37M | · | $37M | |
| Interest Income | $5M | $2M | $3M | $3M | $2M | $5M | $7M | $9M | $3M | $6M | $6M | $1M | $2M | $2M | $4M | $4M | |
| Other Non-op | $16M | $-2M | $8M | $8M | $13M | $-3M | $3M | $15M | $3M | $9M | $10M | $-3M | $6M | $7M | $6M | $-8M | |
| Pretax Income | $412M | $334M | $330M | $328M | $384M | $276M | $299M | $296M | $314M | $266M | $237M | $299M | $317M | $277M | $109M | $351M | |
| Income Tax | $88M | $74M | $81M | $77M | $97M | $59M | $68M | $65M | $74M | $66M | $40M | $68M | $75M | $65M | $-4M | $81M | |
| Net Income | $320M | $252M | $245M | $245M | $282M | $220M | $222M | $226M | $229M | $194M | $192M | $225M | $235M | $202M | $101M | $256M | |
| EPS (Basic) | $2.88 | $2.27 | $2.21 | $2.18 | $2.51 | $1.97 | $1.98 | $2.01 | $2.05 | $1.74 | $1.72 | $1.99 | $2.08 | $1.80 | $0.93 | $2.20 | |
| EPS (Diluted) | $2.84 | $2.24 | $2.18 | $2.16 | $2.47 | $1.94 | $1.95 | $1.99 | $2.03 | $1.72 | $1.70 | $1.96 | $2.05 | $1.78 | $0.92 | $2.17 | |
| Shares (Basic) | 111,000,000 | 110,000,000 | -224,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | -223,000,000 | 112,000,000 | 111,000,000 | 111,000,000 | -224,000,000 | 112,000,000 | 112,000,000 | 112,000,000 | -236,000,000 | 116,000,000 | |
| Shares (Diluted) | 112,000,000 | 112,000,000 | -226,000,000 | 113,000,000 | 113,000,000 | 113,000,000 | -224,000,000 | 113,000,000 | 112,000,000 | 112,000,000 | -228,000,000 | 114,000,000 | 114,000,000 | 113,000,000 | -240,000,000 | 118,000,000 | |
| EBITDA | $605M | $546M | · | $528M | $581M | $486M | · | $455M | $472M | $416M | · | $453M | $460M | $412M | · | $500M |
Bilanz 26
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $626M | $393M | $420M | $432M | $319M | $188M | $549M | $764M | $271M | $474M | · | $143M | $126M | $175M | · | $700M | |
| Receivables | $1.67B | $1.59B | $1.41B | $1.46B | $1.42B | $1.40B | $1.30B | $1.38B | $1.32B | $1.32B | · | $1.28B | $1.24B | $1.25B | · | $1.28B | |
| Inventory | $233M | $225M | $189M | $186M | $187M | $189M | $188M | $184M | $182M | $181M | · | $184M | $184M | $190M | · | $183M | |
| Prepaid Expense | $319M | $361M | $361M | $333M | $273M | $294M | $351M | $299M | $245M | $251M | · | $207M | $188M | $195M | · | $171M | |
| Current Assets | $2.84B | $2.57B | $2.38B | $2.41B | $2.20B | $2.08B | $2.39B | $2.62B | $2.02B | $2.23B | · | $1.81B | $1.73B | $1.81B | · | $2.33B | |
| PP&E (Net) | $2.22B | $2.19B | $2.20B | $2.15B | $2.12B | $2.10B | $2.11B | $2.09B | $1.83B | $1.81B | · | $1.83B | $1.81B | $1.79B | · | $1.71B | |
| PP&E (Gross) | · | · | $6.18B | · | · | · | $5.77B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $3.97B | · | · | · | $3.66B | · | · | · | · | · | · | · | · | · | |
| Goodwill | $9.11B | $9.12B | $8.95B | $8.90B | $8.88B | $8.85B | $8.86B | $8.61B | $7.88B | $7.83B | $7.73B | $7.73B | $7.73B | $7.24B | $7.22B | $7.19B | |
| Intangibles | $1.67B | $1.72B | $1.64B | $1.66B | $1.71B | $1.73B | $1.76B | $1.72B | $1.20B | $1.19B | · | $1.22B | $1.25B | $1.08B | · | $1.11B | |
| Other Non-current Assets | $277M | $256M | $270M | $296M | $271M | $260M | $255M | $272M | $216M | $182M | · | $149M | $152M | $150M | · | $132M | |
| Total Assets | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B | $13.95B | · | $13.48B | $13.43B | $12.79B | · | $13.22B | |
| Accounts Payable | $1.60B | $1.50B | $1.60B | $1.46B | $1.35B | $1.27B | $1.39B | $1.31B | $1.25B | $1.24B | · | $1.16B | $1.20B | $1.20B | · | $1.45B | |
| Accrued Liabilities | · | · | $338M | · | · | · | $306M | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $1.79B | $2.18B | $2.28B | $2.13B | $2.02B | $1.44B | $2.17B | $2.09B | $2.01B | $2.30B | · | $1.62B | $1.88B | $1.35B | · | $1.60B | |
| Capital Leases | $561M | $574M | $537M | $534M | $540M | $538M | $535M | $543M | $507M | $489M | · | $505M | $508M | $490M | · | $505M | |
| Other Non-current Liabilities | $1.06B | $1.02B | $957M | $982M | $890M | $917M | $938M | $891M | $811M | $817M | · | $874M | $901M | $809M | · | $787M | |
| Long-term Debt | $5.64B | · | $5.67B | · | · | · | $6.22B | $6.25B | · | · | · | · | · | · | · | · | |
| Total Debt | $5.64B | $503M | · | $504M | $504M | $1M | · | $6.25B | $606M | $906M | · | $304M | $518M | $2M | · | $2M | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Retained Earnings | $10.37B | $10.15B | $9.99B | $9.84B | $9.68B | $9.49B | $9.36B | $9.22B | $9.08B | $8.94B | · | $8.71B | $8.57B | $8.41B | · | $8.26B | |
| Treasury Stock | $5.17B | $5.09B | $5.18B | $4.90B | $4.77B | $4.79B | $4.86B | $4.73B | $4.76B | $4.78B | · | $4.57B | $4.59B | $4.61B | · | $4.27B | |
| AOCI | $-62M | $-43M | $-27M | $-40M | $-16M | $-83M | $-88M | $-15M | $-19M | $-16M | · | $-20M | $-16M | $-18M | · | $-31M | |
| Stockholders' Equity | $7.52B | $7.37B | $7.17B | $7.26B | $7.23B | $6.93B | $6.78B | $6.81B | $6.62B | $6.43B | · | $6.42B | $6.25B | $6.05B | · | $6.24B | |
| Liabilities + Equity | $16.94B | $16.67B | $16.23B | $16.20B | $15.97B | $15.80B | $16.15B | $16.09B | $13.88B | $13.95B | · | $13.48B | $13.43B | $12.79B | · | $13.22B | |
| Shares Outstanding | 110,000,000 | 111,000,000 | 110,000,000 | 111,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | 112,000,000 | 111,000,000 | 111,000,000 | 111,000,000 | 112,000,000 | 112,000,000 | 112,000,000 | 111,000,000 | 114,000,000 |
Cashflow 16
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $146M | $147M | $145M | $142M | $143M | $140M | $135M | $125M | $117M | $116M | $109M | $111M | $112M | $107M | $116M | $108M | |
| Stock-based Comp | $23M | $20M | $25M | $20M | $21M | $22M | $27M | $19M | $20M | $22M | $19M | $18M | $16M | $24M | $22M | $18M | |
| Deferred Tax | $-2M | $48M | $-13M | $110M | $1M | $7M | $34M | $15M | $-18M | $-18M | $-10M | $-23M | $-12M | $-4M | $-44M | $65M | |
| Amort. of Intangibles | $38M | $37M | $37M | $39M | $39M | $39M | $37M | $32M | $29M | $29M | $27M | $27M | $28M | $26M | $39M | $27M | |
| Restructuring | · | · | · | $6M | $1M | · | · | $7M | $8M | · | · | $1M | $1M | · | · | · | |
| Other Non-cash | · | $-189M | · | · | · | $-75M | · | · | · | $-160M | · | · | · | $-235M | · | · | |
| Operating Cash Flow | $597M | $278M | $465M | $563M | $544M | $314M | $464M | $356M | $360M | $154M | $527M | $207M | $444M | $94M | $334M | $502M | |
| CapEx | $138M | $114M | $158M | $144M | $108M | $117M | $123M | $106M | $92M | $104M | $72M | $105M | $104M | $127M | $147M | $118M | |
| Investing Cash Flow | $-134M | $-152M | $-191M | $-201M | $-124M | $-115M | $-502M | $-1.63B | $-200M | $-213M | $-114M | $-107M | $-682M | $-158M | $-174M | $-118M | |
| Stock Repurchased | · | · | $300M | $150M | · | · | $151M | · | · | · | $275M | $0 | $0 | $0 | $461M | $374M | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Dividends Paid | $96M | $88M | $90M | $89M | $90M | $84M | $84M | $84M | $84M | $79M | $80M | $80M | $80M | $74M | $75M | $78M | |
| Financing Cash Flow | $-229M | $-152M | $-287M | $-247M | $-293M | $-561M | $-170M | $1.77B | $-363M | $-153M | $130M | $-83M | $189M | $-76M | $-545M | $-474M | |
| Net Change in Cash | $233M | $-27M | $-12M | $113M | $131M | $-361M | $-215M | $493M | $-203M | $-212M | $543M | $17M | $-49M | $-140M | $-385M | $-90M | |
| Free Cash Flow | · | $164M | · | · | · | $197M | · | · | · | $50M | · | · | · | $-33M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $13M | · | · | · | $-61M | · | · |
Rentabilität 7
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 15.1% | 13.8% | · | 13.7% | 15.9% | 13.1% | · | 13.3% | 14.8% | 12.7% | · | 14.9% | 14.9% | 13.1% | · | 15.8% | |
| Net Margin | 10.5% | 8.7% | · | 8.7% | 10.2% | 8.3% | · | 9.1% | 9.6% | 8.2% | · | 9.8% | 10.1% | 8.7% | · | 10.3% | |
| Pretax Margin | 13.5% | 11.5% | · | 11.7% | 13.9% | 10.4% | · | 11.9% | 13.1% | 11.2% | · | 13.0% | 13.6% | 11.9% | · | 14.1% | |
| EBITDA Margin | 19.9% | 18.9% | · | 18.8% | 21.0% | 18.3% | · | 18.3% | 19.7% | 17.6% | · | 19.7% | 19.7% | 17.7% | · | 20.1% | |
| ROA | 1.9% | 1.6% | · | 1.5% | 1.9% | 1.5% | · | 1.5% | 1.7% | 1.5% | · | 1.7% | 1.8% | 1.5% | · | 1.9% | |
| ROE | 4.3% | 3.5% | · | 3.5% | 4.1% | 3.3% | · | 3.4% | 3.6% | 3.1% | · | 3.5% | 3.7% | 3.2% | · | 4.0% | |
| ROIC | 2.7% | 4.0% | · | 3.8% | 4.2% | 3.9% | · | 2.0% | 3.8% | 3.1% | · | 3.9% | 3.9% | 3.9% | · | 4.8% |
Liquidität & Solvenz 5
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | 1.2 | · | 1.1 | 1.1 | 1.4 | · | 1.3 | 1.0 | 1.0 | · | 1.1 | 0.9 | 1.3 | · | 1.5 | |
| Quick Ratio | 1.3 | 0.9 | · | 0.9 | 0.9 | 1.1 | · | 1.0 | 0.8 | 0.8 | · | 0.9 | 0.7 | 1.1 | · | 1.2 | |
| Debt / Equity | 0.8 | 0.1 | · | 0.1 | 0.1 | 0.0 | · | 0.9 | 0.1 | 0.1 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | |
| LT Debt / Equity | 0.7 | · | · | · | · | · | · | 0.8 | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | 7.6 | 6.1 | · | 8.3 | 8.9 | 8.2 | · | 10.6 |
Effizienz 3
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | 9.6 | 9.4 | · | 10.1 | 9.9 | 9.7 | · | 9.1 | 8.7 | 8.6 | · | 8.4 | 8.3 | 8.1 | · | 8.3 | |
| Receivables Turnover | 2.0 | 1.9 | · | 2.0 | 2.0 | 1.9 | · | 1.9 | 1.9 | 1.8 | · | 1.8 | 1.8 | 1.8 | · | 1.8 |
Bewertung (TTM) 14
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $11.52B | $11.12B | · | $10.72B | $10.30B | $9.90B | · | $9.55B | $9.40B | $9.33B | · | $9.45B | $9.61B | $9.88B | · | $10.32B | |
| Net Income TTM | $1.10B | $999M | · | $973M | $957M | $869M | · | $874M | $883M | $856M | · | $918M | $927M | $1.05B | · | $1.35B | |
| Market Cap | $23.31B | $21.75B | · | $21.15B | $20.12B | $18.95B | · | $17.39B | $15.19B | $14.78B | · | $13.65B | $15.74B | $15.85B | · | $13.99B | |
| Enterprise Value | $28.33B | $21.86B | · | $21.23B | $20.30B | $18.76B | · | $22.88B | $15.53B | $15.21B | · | $13.81B | $16.13B | $15.67B | · | $13.29B | |
| P/E | 21.8 | 22.2 | · | 22.3 | 21.3 | 22.0 | · | 20.2 | 17.6 | 17.7 | · | 15.3 | 17.7 | 16.0 | · | 11.1 | |
| P/S | 2.0 | 2.0 | · | 2.0 | 2.0 | 1.9 | · | 1.8 | 1.6 | 1.6 | · | 1.4 | 1.6 | 1.6 | · | 1.4 | |
| P/B | 3.1 | 3.0 | · | 2.9 | 2.8 | 2.7 | · | 2.6 | 2.3 | 2.3 | · | 2.1 | 2.5 | 2.6 | · | 2.2 | |
| P / Cash Flow | · | 78.3 | · | · | · | 60.4 | · | · | · | 95.9 | · | · | · | 168.6 | · | · | |
| P / FCF | · | 132.6 | · | · | · | 96.2 | · | · | · | 295.5 | · | · | · | -480.2 | · | · | |
| EV / EBITDA | 46.8 | 40.0 | · | 40.2 | 34.9 | 38.6 | · | 50.3 | 32.9 | 36.6 | · | 30.5 | 35.1 | 38.0 | · | 26.6 | |
| EV / FCF | · | 133.3 | · | · | · | 95.2 | · | · | · | 304.1 | · | · | · | -474.9 | · | · | |
| EV / Revenue | 2.5 | 2.0 | · | 2.0 | 2.0 | 1.9 | · | 2.4 | 1.7 | 1.6 | · | 1.5 | 1.7 | 1.6 | · | 1.3 | |
| Earnings Yield | 4.6% | 4.5% | · | 4.5% | 4.7% | 4.5% | · | 5.0% | 5.7% | 5.6% | · | 6.5% | 5.7% | 6.2% | · | 9.0% | |
| Payout Ratio | · | 34.9% | · | · | · | 38.2% | · | · | · | 40.7% | · | · | · | 36.6% | · | · |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Umsatz | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B |
| Betriebsgewinnmarge % | 14.1% | 13.6% | 13.6% | 14.4% | 22.1% |
| Nettoergebnis | $992M | $871M | $854M | $946M | $2.00B |
| Verwässerte EPS | $8.75 | $7.69 | $7.49 | $7.97 | $15.55 |
Bilanz
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital | 0.8 | 0.9 | 0.7 | 0.7 | 0.6 |
| Liquiditätsgrad | 1.0 | 1.1 | 1.3 | 1.2 | 1.6 |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 1.0 | 1.3 |
Cashflow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Freier Cashflow | $1.36B | $909M | $864M | $1.31B | $1.83B |
Neueste Nachrichten Aktuelle Schlagzeilen über dieses Unternehmen
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
📊
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 1.176 Einreicher · $12.9B gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 115 (-25 vs. Vorquartal) | 64 (-17 vs. Vorquartal) | 415 (+69 vs. Vorquartal) | 333 (-20 vs. Vorquartal) | +7.5M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $1.533.117.858 | 7.233.394 | 11,93% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.299.474.988 | 6.131.045 | 10,11% | Aktien |
| STATE STREET CORP | $1.169.252.484 | 5.516.643 | 9,10% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $584.135.885 | 2.767.754 | 4,54% | Aktien |
| EdgePoint Investment Group Inc. | $476.372.038 | 2.247.568 | 3,71% | Aktien |
| Grantham, Mayo, Van Otterloo & Co. LLC | $400.206.122 | 1.888.207 | 3,11% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $357.050.202 | 1.684.597 | 2,78% | Aktien |
| Davis Selected Advisers | $329.781.509 | 1.555.612 | 2,57% | Aktien |
| VICTORY CAPITAL MANAGEMENT INC | $311.037.928 | 1.467.506 | 2,42% | Aktien |
| NORGES BANK | $298.133.109 | 1.406.620 | 2,32% | Aktien |
| FMR LLC | $227.315.614 | 1.072.496 | 1,77% | Aktien |
| AMERICAN CENTURY COMPANIES INC | $173.422.135 | 818.220 | 1,35% | Aktien |
| M&G PLC | $168.677.800 | 795.650 | 1,31% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $131.756.386 | 621.639 | 1,03% | Aktien |
| ALLIANCEBERNSTEIN L.P. | $122.662.706 | 625.894 | 0,95% | Aktien |
| AMERIPRISE FINANCIAL INC | $109.652.758 | 517.352 | 0,85% | Aktien |
| Woodline Partners LP | $102.974.000 | 485.841 | 0,80% | Aktien |
| FIDUCIARY MANAGEMENT INC /WI/ | $102.489.906 | 483.557 | 0,80% | Aktien |
| Artemis Investment Management LLP | $99.175.856 | 467.921 | 0,77% | Aktien |
| CRAWFORD INVESTMENT COUNSEL INC | $97.514.204 | 460.081 | 0,76% | Aktien |
| PRINCIPAL FINANCIAL GROUP INC | $91.995.201 | 434.042 | 0,72% | Aktien |
| ENVESTNET ASSET MANAGEMENT INC | $90.834.224 | 428.564 | 0,71% | Aktien |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $86.608.697 | 407.302 | 0,67% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $83.772.178 | 395.245 | 0,65% | Aktien |
| M.D. Sass, LLC | $76.397.960 | 360.453 | 0,59% | Aktien |
| Qube Research & Technologies Ltd | $72.783.206 | 343.398 | 0,57% | Aktien |
| MACKENZIE FINANCIAL CORP | $70.641.875 | 333.295 | 0,55% | Aktien |
| Advisors Capital Management, LLC | $69.429.626 | 327.575 | 0,54% | Aktien |
| Swiss National Bank | $65.683.305 | 309.900 | 0,51% | Aktien |
| Balyasny Asset Management L.P. | $58.364.883 | 275.371 | 0,45% | Aktien |
| Mitsubishi UFJ Asset Management Co., Ltd. | $56.877.630 | 268.354 | 0,44% | Aktien |
| RHUMBLINE ADVISERS | $56.744.612 | 267.727 | 0,44% | Aktien |
| BlackRock, Inc. | $55.976.419 | 264.102 | 0,44% | Aktien |
| Sumitomo Mitsui Trust Group, Inc. | $54.809.634 | 258.597 | 0,43% | Aktien |
| VANGUARD ASSET MANAGEMENT, Ltd | $53.654.295 | 253.146 | 0,42% | Aktien |
| Quantinno Capital Management LP | $53.607.358 | 252.924 | 0,42% | Aktien |
| RAYMOND JAMES FINANCIAL INC | $53.249.860 | 251.238 | 0,41% | Aktien |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $52.211.551 | 246.339 | 0,41% | Aktien |
| VAN LANSCHOT KEMPEN INVESTMENT MANAGEMENT N.V. | $51.484.139 | 242.907 | 0,40% | Aktien |
| Clark Capital Management Group, Inc. | $51.259.362 | 241.846 | 0,40% | Aktien |
| Vanguard Global Advisers, LLC | $51.025.267 | 240.742 | 0,40% | Aktien |
| Legal & General Group Plc | $50.185.731 | 236.781 | 0,39% | Aktien |
| FIL Ltd | $49.419.958 | 233.168 | 0,38% | Aktien |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $49.341.000 | 232.797 | 0,38% | Aktien |
| Eurizon Capital SGR S.p.A. | $47.173.414 | 222.564 | 0,37% | Aktien |
| BARCLAYS PLC | $45.003.978 | 212.333 | 0,35% | Aktien |
| PFA Pension, Forsikringsaktieselskab | $43.579.660 | 205.613 | 0,34% | Aktien |
| Integral Health Asset Management, LLC | $42.390.000 | 200.000 | 0,33% | Aktien |
| California Public Employees Retirement System | $41.574.204 | 196.151 | 0,32% | Aktien |
| CONNING INC. | $39.578.271 | 186.734 | 0,31% | Aktien |
| SEB Asset Management AB | $38.766.863 | 182.906 | 0,30% | Aktien |
| BANK OF MONTREAL /CAN/ | $38.512.587 | 181.706 | 0,30% | Aktien |
| GOLDMAN SACHS GROUP INC | $38.322.295 | 180.808 | 0,30% | Aktien |
| Boston Partners | $35.509.632 | 167.514 | 0,28% | Aktien |
| Focus Partners Wealth | $34.616.947 | 163.327 | 0,27% | Aktien |
| STOREBRAND ASSET MANAGEMENT AS | $34.117.592 | 160.970 | 0,27% | Aktien |
| COOKSON PEIRCE & CO INC | $32.977.089 | 155.589 | 0,26% | Aktien |
| UBS Group AG | $32.934.699 | 155.389 | 0,26% | Aktien |
| BRAUN STACEY ASSOCIATES INC | $32.724.232 | 154.396 | 0,25% | Aktien |
| Willis Investment Counsel | $32.110.425 | 151.500 | 0,25% | Aktien |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $31.795.403 | 162.238 | 0,25% | Aktien |
| LPL Financial LLC | $30.325.576 | 143.079 | 0,24% | Aktien |
| APG Asset Management N.V. | $27.869.580 | 150.334 | 0,22% | Aktien |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $26.893.912 | 126.888 | 0,21% | Aktien |
| &PARTNERS | $26.382.365 | 124.363 | 0,21% | Aktien |
| JANE STREET GROUP, LLC | $25.942.680 | 122.400 | 0,20% | Kaufoption |
| BANK OF AMERICA CORP /DE/ | $25.492.499 | 120.276 | 0,20% | Aktien |
| Candriam S.C.A. | $25.459.925 | 120.238 | 0,20% | Aktien |
| Squarepoint Ops LLC | $24.974.280 | 117.831 | 0,19% | Aktien |
| Gotham Asset Management, LLC | $24.911.119 | 117.533 | 0,19% | Aktien |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $24.607.896 | 116.373 | 0,19% | Aktien |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $24.569.456 | 115.921 | 0,19% | Aktien |
| Robeco Institutional Asset Management B.V. | $23.854.123 | 112.546 | 0,19% | Aktien |
| AEGON ASSET MANAGEMENT UK Plc | $22.866.862 | 107.888 | 0,18% | Aktien |
| TOCQUEVILLE ASSET MANAGEMENT L.P. | $22.670.926 | 106.964 | 0,18% | Aktien |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $22.530.921 | 106.303 | 0,18% | Aktien |
| MERCER GLOBAL ADVISORS INC /ADV | $22.106.507 | 104.301 | 0,17% | Aktien |
| Moran Wealth Management, LLC | $22.053.609 | 104.051 | 0,17% | Aktien |
| ABN AMRO Bank N.V. | $21.523.733 | 101.667 | 0,17% | Aktien |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $21.496.202 | 123.876 | 0,17% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $21.322.170 | 100.600 | 0,17% | Kaufoption |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $21.146.252 | 99.770 | 0,16% | Aktien |
| AVIVA PLC | $20.378.569 | 96.148 | 0,16% | Aktien |
| SCHWARTZ INVESTMENT COUNSEL INC | $20.326.005 | 95.900 | 0,16% | Aktien |
| Boston Common Asset Management, LLC | $20.282.767 | 95.696 | 0,16% | Aktien |
| CAPTRUST FINANCIAL ADVISORS | $20.146.790 | 95.054 | 0,16% | Aktien |
| Midwest Trust Co | $20.113.207 | 94.896 | 0,16% | Aktien |
| LAZARD ASSET MANAGEMENT LLC | $20.035.210 | 94.528 | 0,16% | Aktien |
| FJARDE AP-FONDEN /FOURTH SWEDISH NATIONAL PENSION FUND | $19.842.759 | 93.620 | 0,15% | Aktien |
| BLAIR WILLIAM & CO/IL | $19.773.115 | 93.291 | 0,15% | Aktien |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $19.613.005 | 92.536 | 0,15% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $19.160.280 | 90.400 | 0,15% | Verkaufsoption |
| CITADEL ADVISORS LLC | $18.821.160 | 88.800 | 0,15% | Kaufoption |
| WELLINGTON MANAGEMENT GROUP LLP | $17.507.282 | 82.601 | 0,14% | Aktien |
| Foundry Partners, LLC | $17.338.432 | 102.473 | 0,13% | Aktien |
| MARSHALL WACE, LLP | $17.187.874 | 81.094 | 0,13% | Aktien |
| Coho Partners, Ltd. | $16.981.317 | 89.103 | 0,13% | Aktien |
| Copeland Capital Management, LLC | $16.902.800 | 79.749 | 0,13% | Aktien |
| CIBC Asset Management Inc | $16.674.318 | 78.671 | 0,13% | Aktien |
| Mitsubishi UFJ Trust & Banking Corp | $16.558.594 | 78.125 | 0,13% | Aktien |
Unternehmensinsider 53 Insider · 26 Führungskräfte · 26 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| E. J. Davis | CEO and President | 1. Juni 2026 S | 132.423 | 0 | 5 | $-14.656.302 |
| Surya N Mohapatra | Chairman, President & CEO | 30. April 2012 F | 243.713 | 0 | 0 | $0 |
| Sam Samad | Executive Vice President & CFO | 22. Juli 2026 A | 33.478 | 0 | 0 | $0 |
| Mark Guinan | Executive Vice President & CFO | 7. März 2022 F | 98.981 | 0 | 0 | $0 |
| Robert Hagemann | SVP & Chief Financial Officer | 5. März 2013 F | 126.722 | 0 | 0 | $0 |
| Mark E Delaney | SVP & Chief Commercial Officer | 28. Juli 2026 S | 10.335 | 0 | 1 | $-376.288 |
| Karthik Kuppusamy | SVP, Clinical Solutions | 22. Juli 2026 L | 13.557 | 0 | 2 | $-2.167.772 |
| Patrick Plewman | SVP for Diagnostic Services | 22. Juli 2026 L | 15.293 | 0 | 4 | $-2.194.322 |
| Catherine T. Doherty | EVP, Regional Businesses | 5. März 2026 S | 67.122 | 0 | 7 | $-6.671.228 |
| Michael E Prevoznik | SVP & General Counsel | 5. März 2026 S | 37.557 | 0 | 7 | $-6.505.199 |
| Michael J Deppe | SVP, Corp. Controller & CAO | 4. März 2026 F | 35.196 | 0 | 0 | $0 |
| Mark A Gardner | SVP of Molecular Gen & Oncol | 24. September 2024 F | 4.673 | 0 | 0 | $0 |
| Manner Carrie Eglinton | SVP, Advanced Diagnostics | 7. März 2022 F | 48.391 | 0 | 0 | $0 |
| Manuel O. Mendez | SVP & Chief Commercial Officer | 17. Februar 2021 A | 29.045 | 0 | 0 | $0 |
| Robert A Klug | VP, Corporate Controller | 1. März 2019 F | 6.261 | 0 | 0 | $0 |
| Jon R Cohen | SVP & Group Exec. Diag. Sol. | 8. März 2018 M | 31.757 | 0 | 0 | $0 |
| Everett Cunningham | SVP, Commercial | 1. März 2018 G | 37.760 | 0 | 0 | $0 |
| Thomas F Bongiorno | VP and Corporate Controller | 2. März 2015 F | 11.837 | 0 | 0 | $0 |
| John B. Haydon | SVP, Operations | 13. Februar 2014 A | 19.890 | 0 | 0 | $0 |
| Kathy Ordonez | SVP, Diagnostic Solutions | 31. März 2013 F | 9.569 | 0 | 0 | $0 |
| Joan Elizabeth Miller | SVP-Oncology & Neurology Srvcs | 29. Februar 2012 F | 89.232 | 0 | 0 | $0 |
| Wayne R. Simmons | Vice President, Operations | 16. Juni 2011 M | 47.150 | 0 | 0 | $0 |
| Robert E Peters | VP, Sales & Marketing | 12. Februar 2007 A | 12.974 | 0 | 0 | $0 |
| David M Zewe | SVP, Diagnostic Testing Ops | 12. Februar 2007 A | 31.079 | 0 | 0 | $0 |
| GRANT THOMAS W II | Sr VP, Ins. & Employer Serv. | 12. Februar 2007 A | — | 0 | 0 | $0 |
| Gerald C Marrone | SVP, Administration | 28. Februar 2004 F | 49.609 | 0 | 0 | $0 |
| Wright Lassiter III | Direktor | 22. Juli 2026 L | 10.323 | 0 | 0 | $0 |
| Vicky B Gregg | Direktor | 22. Juli 2026 A | 18.386 | 0 | 1 | $-239.700 |
| Robert B Carter | Direktor | 22. Juli 2026 L | 3.864 | 0 | 0 | $0 |
| Timothy L Main | Direktor | 22. Juli 2026 L | 22.460 | 0 | 0 | $0 |
| Timothy C Wentworth | Direktor | 1. Juli 2026 A | 1.358 | 0 | 0 | $0 |
| Timothy M Ring | Direktor | 20. Mai 2026 A | 31.140 | 0 | 0 | $0 |
| Gary M Pfeiffer | Direktor | 20. Mai 2026 A | 31.005 | 0 | 1 | $-270.317 |
| Luis Diaz | Direktor | 15. Mai 2025 A | 4.054 | 0 | 0 | $0 |
| Tracey Doi | Direktor | 15. Mai 2025 A | 6.490 | 0 | 0 | $0 |
| Gail R Wilensky | Direktor | 17. Mai 2023 A | 20.506 | 0 | 0 | $0 |
| Stephen H Rusckowski | Direktor | 6. März 2023 F | 389.597 | 0 | 0 | $0 |
| Helen Torley | Direktor | 25. Mai 2021 A | 6.260 | 0 | 0 | $0 |
| Daniel Stanzione | Direktor | 23. November 2020 S | 28.349 | 0 | 0 | $0 |
| Jenne K Britell | Direktor | 4. Juni 2018 G | 14.479 | 0 | 0 | $0 |
| Jeffrey M Leiden | Direktor | 29. Mai 2018 S | 6.000 | 0 | 0 | $0 |
| John B Ziegler | Direktor | 22. Februar 2017 S | 16.557 | 0 | 0 | $0 |
| John C Baldwin MD | Direktor | 12. August 2015 S | 12.949 | 0 | 0 | $0 |
| William F Buehler | Direktor | 12. Februar 2014 M | 26.225 | 0 | 0 | $0 |
| GSK plc | Direktor | 31. Januar 2011 S | 0 | 0 | 0 | $0 |
| Rosanne Haggerty | Direktor | 6. Mai 2010 A | 9.334 | 0 | 0 | $0 |
| William R Grant | Direktor | 1. April 2007 A | 3.334 | 0 | 0 | $0 |
| James F Flaherty III | Direktor | 4. Mai 2006 A | 1.667 | 0 | 0 | $0 |
| Kenneth D Brody | Direktor | 28. April 2004 S | 0 | 0 | 0 | $0 |
| Mary A Cirillo | Direktor | 1. April 2004 A | 2.627 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 13 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Quest Diagnostics Incorporated | 18. Mai 2011 | — | Erste Einreichung | M&A / Verkauf | SEC |
| Nicht offengelegter meldender Beteiligter | 1. Februar 2011 | — | Erste Einreichung | Passive Anlage | SEC |
| Nicht offengelegter meldender Beteiligter | 20. März 2009 | — | Erste Einreichung | — | SEC |
| GlaxoSmithKline plc ×2 Einreichungen | 18. September 2008 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter | 16. Februar 2007 | — | Erste Einreichung | — | SEC |
| Quest Diagnostics Incorporated - (FEIN No. ×2 Einreichungen | 19. Januar 2006 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter | 15. Dezember 2004 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter | 29. Juni 2004 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter | 24. Juni 2002 | — | Erste Einreichung | M&A / Verkauf | SEC |
| Nicht offengelegter meldender Beteiligter | 22. Mai 2002 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter | 12. April 2002 | — | Erste Einreichung | M&A / Verkauf | SEC |
| IRS Identification Nos. of Above Persons (entities only) Quest Diagnostics Ventures LLC - (FEIN No., Quest Diagnostics Incorporated - (FEIN No. ×3 Einreichungen | 1. November 2001 | — | Erste Einreichung | M&A / Verkauf | SEC |
| Nicht offengelegter meldender Beteiligter | 14. Mai 2001 | — | Erste Einreichung | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 192 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| IHF · iShares Trust | 3,93% | 199.039 SH | 21. August 2026 | Täglich |
| FTDS · First Trust Exchange-Traded Fund | 2,17% | 3.760 NS | 30. Juni 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,71% | 58.159 SH | 21. August 2026 | Täglich |
| GK · AdvisorShares Trust | 1,43% | 2.156 NS | 30. Juni 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 1,29% | 57.932 NS | 30. April 2026 | N-PORT |
| CZA · Invesco Exchange-Traded Fund Trust | 1,24% | 9.488 SH | 21. August 2026 | Täglich |
| TMFX · RBB Fund, Inc. | 1,05% | 1.724 NS | 31. Mai 2026 | N-PORT |
| ANEW · ProShares Trust | 0,92% | 364 NS | 31. Mai 2026 | N-PORT |
| QLTY · GMO ETF Trust | 0,85% | 196.208 NS | 31. Mai 2026 | N-PORT |
| ALTL · Pacer Funds Trust | 0,82% | 4.047 NS | 30. April 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,80% | 635 NS | 30. April 2026 | N-PORT |
| SPVM · Invesco Exchange-Traded Fund Trust | 0,78% | 4.426 SH | 21. August 2026 | Täglich |
| QLV · FlexShares Trust | 0,74% | 6.461 NS | 30. April 2026 | N-PORT |
| GDOC · Goldman Sachs ETF Trust | 0,72% | 741 NS | 31. Mai 2026 | N-PORT |
| ESMV · iShares Trust | 0,72% | 236 SH | 21. August 2026 | Täglich |
| PAPI · Morgan Stanley ETF Trust | 0,56% | 10.542 NS | 30. Juni 2026 | N-PORT |
| HUSV · First Trust Exchange-Traded Fund III | 0,52% | 1.956 NS | 30. April 2026 | N-PORT |
| PRAY · FIS Trust | 0,47% | 1.958 NS | 31. Mai 2026 | N-PORT |
| ITAN · EA Series Trust | 0,46% | 2.110 NS | 29. Mai 2026 | N-PORT |
| BTAL · AGF Investments Trust | 0,46% | 6.072 NS | 30. Juni 2026 | N-PORT |
| KNGZ · First Trust Exchange-Traded Fund VI | 0,44% | 1.301 NS | 30. Juni 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 0,44% | 1.055 NS | 30. April 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 0,44% | 409.814 NS | 30. April 2026 | N-PORT |
| FVD · First Trust Exchange-Traded Fund | 0,43% | 161.912 NS | 30. Juni 2026 | N-PORT |
| SIXL · EXCHANGE TRADED CONCEPTS TRUST | 0,41% | 3.999 NS | 31. Mai 2026 | N-PORT |
| IYH · iShares Trust | 0,41% | 65.931 SH | 21. August 2026 | Täglich |
| VOE · VANGUARD INDEX FUNDS | 0,40% | 711.079 SH | 19. August 2026 | Täglich |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,38% | 8.682 NS | 30. April 2026 | N-PORT |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0,37% | 8.368 NS | 30. April 2026 | N-PORT |
| IMCV · iShares Trust | 0,37% | 18.030 SH | 21. August 2026 | Täglich |
| SUSA · iShares Trust | 0,35% | 59.963 SH | 21. August 2026 | Täglich |
| FHLC · FIDELITY COVINGTON TRUST | 0,35% | 51.278 NS | 30. April 2026 | N-PORT |
| FTA · First Trust Exchange-Traded AlphaDE… | 0,34% | 23.030 NS | 30. April 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,34% | 330.273 SH | 19. August 2026 | Täglich |
| IXJ · iShares Trust | 0,32% | 58.047 SH | 21. August 2026 | Täglich |
| RXL · ProShares Trust | 0,31% | 1.147 NS | 31. Mai 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0,31% | 2.194 NS | 30. April 2026 | N-PORT |
| GNOM · Global X Funds | 0,28% | 789 NS | 31. Mai 2026 | N-PORT |
| DFLV · Dimensional ETF Trust | 0,26% | 79.983 NS | 30. April 2026 | N-PORT |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0,26% | 7.703.000 | 19. August 2026 | Täglich |
| IWS · iShares Trust | 0,25% | 166.379 SH | 21. August 2026 | Täglich |
| FEX · First Trust Exchange-Traded AlphaDE… | 0,24% | 18.806 NS | 30. April 2026 | N-PORT |
| JVAL · J.P. Morgan Exchange-Traded Fund Tr… | 0,24% | 8.995 NS | 30. April 2026 | N-PORT |
| EQIN · Columbia ETF Trust I | 0,23% | 3.340 NS | 30. April 2026 | N-PORT |
| CVMC · Morgan Stanley ETF Trust | 0,23% | 1.137 NS | 30. Juni 2026 | N-PORT |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 0,23% | 26.229 NS | 30. April 2026 | N-PORT |
| SIZE · iShares Trust | 0,23% | 4.242 SH | 21. August 2026 | Täglich |
| DFVE · DoubleLine ETF Trust | 0,23% | 351 NS | 30. Juni 2026 | N-PORT |
| VO · VANGUARD INDEX FUNDS | 0,23% | 2.398.948 SH | 19. August 2026 | Täglich |
| EUSA · iShares, Inc. | 0,22% | 18.045 SH | 21. August 2026 | Täglich |